BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Nations Jockey for COVID-19 Vaccine, Create ‘Vaccine Nationalism’

  Even before a vaccine for the novel coronavirus has been completely developed, nations across the globe are jockeying for position to lay claim for the potential preventative medicine in something of a healthcare arms race.

  July 10, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  BioNTech CEO Believes COVID-19 Vaccine Could be Ready for Approval by December

  BioNTech Chief Executive Officer Ugur Sahin predicts the company’s vaccine for COVID-19, which is it co-developing with Pfizer, could be ready for regulatory approval by the end of the year, with hundreds of millions of doses available for immediate distribution.

  July 10, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Clinical Catch-Up: July 6-10

  Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.

  July 10, 2020

   · 

  10 min read

   · 

  Mark Terry
• 

  Drug Development

  Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS

  Biogen announced on Wednesday that it has seen positive results from its Phase I/II study of tofersen, also known as BIIB067, for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

  July 10, 2020

   · 

  3 min read

   · 

  Krystle Vermes
• 

  Biotech Bay

  Transfusing Blood From Physically Fit Mice into “Couch Potato” Mice Improves Brain Function

  Researchers at the University of California, San Francisco, working with mice, found that by taking blood from mice that exercised regularly and giving it to “couch potato” mice, re-energized the brains of the non-active mice.

  July 10, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Atox Bio’s Reltecimod Shows Effectiveness in Flesh-Eating Bacterial Infections

  Reltecimod is a synthetic peptide antagonist of both superantigen exotoxins and the CD28 T-cell costimulatory receptor.

  July 10, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Biopharma Giants Back Launch of AMR Fund with $1 Billion

  A collective of pharmaceutical companies, including Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, has pledged financial support of approximately $1 billion to support the Antimicrobial Resistance Action Fund.

  July 10, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Pharm Country

  Blackstone life sciences Closes $4.6 Billion Life Sciences Fund

  Blackstone announced its Blackstone Life Sciences V fund closed at its hard cap of $4.6 billion of total capital commitments, making it the largest life sciences private fund that has been raised to date.

  July 10, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Gilead: Remdesivir Demonstrates Broader Effectiveness Against COVID-19

  Gilead Sciences reported additional data from its Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19.

  July 10, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Cancer Stakeholders Call for Consensus of Terms to Encourage Patients’ Genetic Testing

  Cancer patients aren’t getting the testing they need for precision medicine, partially because of pervasive confusion regarding terminology, according to a whitepaper released July 7 by the Consistent Testing Terminology Working Group.

  July 10, 2020

   · 

  5 min read

   · 

  Gail Dutton